EGFR and melanoma: Foretinib (F, MET inhibitor) and lapatinib (L, EGFR inhibitor) used simultaneously were able to synergistically decrease the viability of melanoma cells, and also significantly diminish the invasive abilities and proteolytic activity of these cells [10,11].